PF-06741086 Long-term Treatment in Severe Hemophilia

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 25% of the time (96 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectslong termpfterm safetythe long
  Phrases that lowered it: evaluateupperefficacyscreeninglimit of
• Sponsor's past termination rate: 16.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 1742 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: sequential (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 6 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 137 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Maximum age: 74 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PF-06741086 Multiple Dose Study in Severe Hemophilia NCT02974855 · started 2017 · scored riskier than 72% of active trials completed
• Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia NCT04878731 · started 2021 · scored riskier than 26% of active trials completed
• Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia NCT01439971 · started 2011 · scored riskier than 14% of active trials completed
• Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B NCT03995784 · started 2019 · scored riskier than 6% of active trials completed
• Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A NCT01775618 · started 2013 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.